Search clinical trials for: high risk adenocarcinoma

Total 40932 results

City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation

Thyroid Gland Follicular Carcinoma | Thyroid Gland Papillary Carcinoma | Thyroid Gland Oncocytic Carcinoma

United States
Obstetrics & Gynecology Hospital of Fudan University
Peking Union Medical College Hospital; First Affiliated Hospital of Xinjiang... and other collaborators

Not yet recruiting

Role of Methylation Test Triage in HPV Positive Women (MTTRIHPW)

Precancerous Cervical Lesion

China
Peking University First Hospital
Jiangsu Hengrui Pharmaceutical Co., Ltd.; Beijing Biote Pharmaceutical Co.,Ltd

Recruiting

Adjuvant Rezvilutamide in Combination With Androgen Deprivation Therapy in Androgen Receptor-positive, High-risk Salivary Duct Carcinoma

Salivary Gland Neoplasm Duct

China
Masaryk Memorial Cancer Institute
Masaryk University

Recruiting

Pancreatic Cancer Screening in a Population at High Risk (ScrePan)

Pancreatic Ductal Adenocarcinoma | Pancreatitis, Chronic | Hereditary Diseases

Czechia
Chang Gung Memorial Hospital
Ministry of Health and Welfare, Taiwan

Recruiting

Innovative Diagnosis and Therapy in LDLT Patients With High-risk Hepatocellular Carcinoma

High Risk of Recurrence

Taiwan
Memorial Sloan Kettering Cancer Center

Recruiting

A Study of Early Cancer Detection in People at High Risk of Developing Pancreatic Ductal Adenocarcinoma (PDAC)

Pancreatic Cyst

United States
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Chemotherapy Combined With Adebrelimab and Apatinib as the Perioperative Treatment in Patients With Biliary Tract Cancer

Resectable Intrahepatic Cholangiocarcinoma With High Risk of Recurrence

China
Jinling Hospital, China

Recruiting

A Study of Multimodal Radiotherapy for Renal Cell Carcinoma Progressed After Prior Immunotherapy

Renal Cell Carcinoma | Radiotherapy | Immune Checkpoint Inhibitor

China
The First Affiliated Hospital with Nanjing Medical...
Jiangsu Hengrui Pharmaceutical Co., Ltd.

Recruiting

Neoadjuvant Therapy of HAIC（GEMOX） Combined With Adebrelimab and Lenvatinib for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors

Intrahepatic Cholangiocarcinoma

China
Mayo Clinic

Recruiting

A Prospective Registry for Patients at High-Risk for Pancreatic Cancer

Pancreatic Cancer | Pancreatic Ductal Adenocarcinoma | PDAC | PDAC - Pancreatic Ductal Adenocarcinoma

United States
Tianjin Third Central Hospital
BGI, China

Recruiting

A Prospective Study on the Application of Liquid Biopsy in the Surveillance of High-risk Population of HCC.

Hepatocellular Carcinoma

China
Dana-Farber Cancer Institute

Recruiting

Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals

Pancreatic Cancer | Pancreatic Ductal Adenocarcinoma | Pancreatic Neoplasm | PDAC | PDAC - Pancreatic Ductal Adenocarcinoma

United States
National Cancer Institute (NCI)

Recruiting

Durvalumab With Gemcitabine and Cisplatin for the Treatment of High Risk Resectable Liver Cancer Before Surgery

Resectable Intrahepatic Cholangiocarcinoma

United States
University of Texas Southwestern Medical Center
Telix International Pty Ltd; Once Upon a Time Foundation

Recruiting

PSMA PET Response Guided SabR in High Risk Pca

Prostate Adenocarcinoma

United States
Peking Union Medical College Hospital

Not yet recruiting

Adjuvant Therapy for High-risk Hepatocellular Carcinoma Post Liver Transplantation

Liver Transplant; Complications | Recurrent Osteosarcoma | Hepatocarcinoma | High-Risk Cancer

China
Gruppo Oncologico del Nord-Ovest

Recruiting

CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative Chemotherapy Versus Immediate Resection in patIents With resecTable BiliarY Tract Cancers (BTC) at High Risk for Recurrence (PURITY)

Cholangiocarcinoma | Biliary Tract Cancer

Italy
National Cancer Institute (NCI)

Not yet recruiting

Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer

Breast Carcinoma | Breast Ductal Carcinoma In Situ | Breast Lobular Carcinoma In Situ | Breast Atypical Hyperplasia

United States
Comprehensive Cancer Centre The Netherlands

Recruiting

High-Risk prostatE Cancer radiatiOn Versus surgERy (RECOVER)

Prostate Cancer | Prostate Adenocarcinoma

Netherlands
Zhejiang Cancer Hospital

Recruiting

Lenvatinib Combined With Tislelizumab and TACE Applied as Neoadjuvant Regimen for the Patients of CNLC Stage IB and IIA Hepatocellular Carcinoma With High-risk Recurrence Factors

Hepatocellular Carcinoma | Oxaliplatin | TACE | Lenvatinib | Tislelizumab | Pharmorubicin

China
Catalysis SL
Atika Pharma S.L.

Recruiting

Evaluation Of The Efficacy Of The Combination Of GLIZIGEN® Oral Solution 1/Day And Vaginal Gel 1/Night For 2 Months In Patients With Cervical Intraepithelial Neoplasia Grade 1 (LSIL/CIN-1) Caused By High-Risk Human Papillomavirus (HPV-AR)

Papilloma Viral Infection | CIN1 | LSIL, Low Grade Squamous Intraepithelial Lesion

Spain
Guangxi Medical University

Not yet recruiting

Adjuvant Tislelizumab Plus Lenvatinib for Patients at High-risk of HCC Recurrence After Curative Resection or Ablation (PREVENT-2)

Recurrence | Hepatocellular Carcinoma | Immune Checkpoint Inhibitor

China
Sun Yat-sen University

Recruiting

HAIC Plus A+T for Patients With High-risk HCC: a Single-arm Phase 2 Trial

Hepatocellular Carcinoma

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.

Hepatocellular Carcinoma

China
SWOG Cancer Research Network
National Cancer Institute (NCI)

Recruiting

Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation

Prostate Adenocarcinoma | Stage IIIB Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8

United States
The Affiliated Nanjing Drum Tower Hospital of Nanjing...

Recruiting

Postoperative Adjuvant Therapy for Non-clear Renal Cell Carcinoma With High-risk Recurrence Factors (IUNU-RC)

Non-clear Renal Cell Carcinoma

China
University of Chicago

Recruiting

A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer

Prostate Cancer | Prostate Adenocarcinoma

United States
Zhongshan Hospital (Xiamen), Fudan University

Recruiting

Study on Screening, Verification and Intervention of High-risk Patients With Liver Cancer

Hepatocellular Carcinoma | Chronic Hepatitis B

China
Tianjin Medical University Cancer Institute and...

Recruiting

Durvalumab Combined With GemCis Neoadjuvant Therapy of Resectable Intrahepatic Cholangiocarcinoma With High Recurrence Risk

Intrahepatic Cholangiocarcinoma | Durvalumab | Gemcis

China
Federation Francophone de Cancerologie Digestive

Not yet recruiting

Study Evaluating the Benefit of Adding Ipilimumab to the Combination of Atezolizumab and Bevacizumab in Patients With Hepatocellular Carcinoma Receiving First-line Systemic Therapy (TRIPLET)

Metastatic Cancer | Metastatic Tumor | HCC - Hepatocellular Carcinoma

France
Erasmus Medical Center
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Recruiting

Preoperative Radiotherapy in Patients at High Risk of Postoperative Pancreatic Fistula After Pancreatoduodenectomy (FIBROPANC-1)

Pancreatic Fistula | Pancreas Neoplasm | GIST | Neuroendocrine Carcinoma of Pancreas | Duodenum Carcinoma | Distal Cholangiocarcinoma | Pancreas Fibrosis

Netherlands
Peking Union Medical College Hospital
Tongji Hospital; Beijing Hospital; The First Affiliated Hospital of Xiamen University

Not yet recruiting

A Cohort Study on Screening and Follow-up of High-risk Population of PDAC Based on EUS

Carcinoma, Pancreatic Ductal
Tianjin Medical University Cancer Institute and...

Not yet recruiting

HAIC or Lenvatinib Combined With Sintilimab for High Recurrence Risk Resectable Solitary Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Northwestern University
National Cancer Institute (NCI)

Recruiting

Therasphere® and Systemic Therapy for Patients With Hepatocellular Carcinoma That is High-risk

Hepatocellular Carcinoma

United States
Zhejiang Cancer Hospital

Recruiting

GOT Applied as Neoadjuvant Regimen for Patients of Resectable ICC With High-risk Factors of Recurrence (GOT)

Intrahepatic Cholangiocarcinoma

China
Henan Cancer Hospital

Not yet recruiting

Study of Donafenib Combined With Tislelizumab in the Adjuvant Treatment of Primary HCC With High Risk of Recurrence

Hepatocellular Carcinoma
Rana McKay, MD
University of California, San Diego; AstraZeneca

Recruiting

Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With BRCA1/2 Gene Alterations (NePtune)

Prostate Cancer | BRCA1 Mutation | BRCA2 Mutation | Prostatic Adenocarcinoma | High-Risk Cancer

United States
Akeso

Not yet recruiting

A Phase III Study of AK104 as Adjuvant Therapy in HCC With High Risk of Recurrence After Curative Resection

Hepatocellular Carcinoma

China
Dana-Farber Cancer Institute

Recruiting

InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer

Lung Cancer | Cirrhosis | Barrett Esophagus | Hematologic Malignancy | Non-Alcoholic Fatty Liver Disease | Cancer Risk | Vulvar Intraepithelial Neoplasia | Childhood Cancer Survivors | Lung; Node | Non Alcoholic Steatohepatitis | Osteochondroma | Cancer Predisposition Syndrome | Hereditary Cancer Prediction | Adult... and other conditions

United States
West Virginia University

Recruiting

Safety and Feasibility of HIPEC for High-Risk Gallbladder Adenocarcinoma

Gallbladder Adenocarcinoma

United States
Anhui Provincial Hospital
Henan Cancer Hospital; First Affiliated Hospital Xi'an Jiaotong University; First...

Recruiting

A Study to Evaluate Tislelizumab Combined With Sitravatinib as Adjuvant Therapy in Participants With HCC at High Risk of Recurrence After Curative Resection

Hepatocellular Carcinoma

China
Newish Technology (Beijing) Co., Ltd.
Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Recruiting

NewishT Cell Therapy for HCC With High Risk of Recurrence After Radical Resection

Hepatocellular Carcinoma

China
Laval University

Recruiting

Diagnostic Value of DWI-MRI for Detection of Peritoneal Metastases in High-risk Pancreatic Ductal Adenocarcinoma. (DWI-PDAC)

Pancreas Adenocarcinoma | Pancreas Cancer, Duct Cell Adenocarcinoma | Peritoneal Carcinomatosis | Peritoneal Metastases

Canada
Johns Hopkins University
King Faisal Specialist Hospital and Research Center in Riyadh (Saudi Arabia) and other collaborators

Recruiting

International Study of High-Risk Patients for Hepatocellular Carcinoma Using Liquid Biopsy (STOP-HCC)

Liver Cirrhosis | Hepatocellular Carcinoma | Liver Cancer | Early Stage Liver Cancer

Saudi Arabia, Vietnam
Fondazione IRCCS Istituto Nazionale dei Tumori,...

Recruiting

Adjuvant CAPECITABINE in High Risk PSEUDOMYXOMA PERITONEI Patients (ACAPP)

Pseudomyxoma Peritonei

Italy
Fudan University

Recruiting

HAIC Combined With Anlotinib and TQB2450 as Adjuvant Therapy in HCC Patients With High Risk of Recurrence After Resection

Hepatocarcinoma

China
Beth Israel Deaconess Medical Center
Dana-Farber Cancer Institute; National Institutes of Health (NIH)

Not yet recruiting

Panc CA Risk Model & Biomarker Testing In High-Risk Cohort

Pancreatic Adenocarcinoma

United States
Zhang Dazhi,MD
The Affiliated Hospital Of Southwest Medical University; Chongqing Public Health... and other collaborators

Not yet recruiting

Clinical Intervention Strategy for High-risk Group of Hepatitis B Related Hepatocellular Carcinoma

Time
Chinese PLA General Hospital
Immunotech Applied Science Ltd.

Recruiting

Expanded Activated Lymphocytes (EAL) as Adjuvant Therapy in Patients With HCC at High Risk of Recurrence After Radical Resection

Hepatocellular Carcinoma (HCC)

China
Peking University People's Hospital
Hangzhou Newhorizon Health Technology Co., Ltd.; Hangzhou Mingze Medical Research... and other collaborators

Recruiting

Clinical Evaluation of Detection of High Risk HPV in Urine (Urine-hrHPV)

Cervical Cancer | Cervical Adenocarcinoma | Cervical Squamous Cell Carcinoma | Human Papillomavirus Infection | Human Papilloma Virus | Adenocarcinoma in Situ | High-Grade Squamous Intraepithelial Lesions | Cervical Intraepithelial Neoplasia Grade II | Cervical Intraepithelial Neoplasia, Grade III | Atypical... and other conditions

China
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Recruiting

Regorafenib and Durvalumab for the Treatment of High-Risk Liver Cancer

Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IB Hepatocellular Carcinoma AJCC v8 | Stage II Hepatocellular Carcinoma AJCC v8

United States

Search clinical trials for: high risk adenocarcinoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Vietnam

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations